| Epstein-Barr virus infection |
2.50 |
0.00e+0 |
189/202 (93.56%) |
CDKN1A;DDB2;ISG15;...
|
| p53 signaling pathway |
2.37 |
0.00e+0 |
63/73 (86.3%) |
CDKN1A;SESN1;DDB2;...
|
| Herpes simplex virus 1 infection |
2.26 |
0.00e+0 |
165/498 (33.13%) |
FAS;IRF9;BAX;...
|
| Graft-versus-host disease |
2.18 |
0.00e+0 |
32/42 (76.19%) |
FAS;HLA-B;IL1B;...
|
| Influenza A |
2.14 |
0.00e+0 |
156/172 (90.7%) |
TNFRSF10B;FAS;IRF9;...
|
| Measles |
2.12 |
0.00e+0 |
133/139 (95.68%) |
FAS;IRF9;BAX;...
|
| Lysosome |
2.11 |
0.00e+0 |
115/128 (89.84%) |
FUCA1;AP1S2;TPP1;...
|
| Kaposi sarcoma-associated herpesvirus infection |
2.11 |
0.00e+0 |
172/193 (89.12%) |
CDKN1A;FAS;IRF9;...
|
| Small cell lung cancer |
2.10 |
0.00e+0 |
90/92 (97.83%) |
CDKN1A;DDB2;BAX;...
|
| Viral myocarditis |
2.05 |
0.00e+0 |
53/60 (88.33%) |
HLA-B;CXADR;HLA-F;...
|
| Hepatitis C |
2.02 |
0.00e+0 |
139/157 (88.54%) |
CDKN1A;FAS;IRF9;...
|
| C-type lectin receptor signaling pathway |
1.99 |
0.00e+0 |
93/104 (89.42%) |
EGR2;IRF9;RELB;...
|
| NF-kappa B signaling pathway |
1.95 |
2.65e-3 |
90/104 (86.54%) |
RELB;GADD45A;TNFAIP3;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.92 |
4.10e-3 |
84/100 (84%) |
TNFRSF10B;CCL20;CXCL13;...
|
| Type I diabetes mellitus |
1.91 |
3.82e-3 |
38/43 (88.37%) |
FAS;HLA-B;IL1B;...
|
| Apoptosis |
1.89 |
4.30e-3 |
126/168 (75%) |
TNFRSF10B;FAS;BAX;...
|
| Cytosolic DNA-sensing pathway |
1.89 |
4.05e-3 |
52/63 (82.54%) |
IRF7;IL1B;NFKBIA;...
|
| Allograft rejection |
1.87 |
4.46e-3 |
32/38 (84.21%) |
FAS;HLA-B;HLA-F;...
|
| Autoimmune thyroid disease |
1.86 |
4.23e-3 |
46/53 (86.79%) |
FAS;HLA-B;HLA-F;...
|
| Pancreatic cancer |
1.86 |
4.02e-3 |
75/76 (98.68%) |
CDKN1A;DDB2;BAX;...
|
| Cytokine-cytokine receptor interaction |
1.86 |
3.82e-3 |
246/295 (83.39%) |
TNFRSF10B;FAS;IL32;...
|
| TNF signaling pathway |
1.85 |
4.17e-3 |
103/112 (91.96%) |
FAS;TNFAIP3;JAG1;...
|
| Th1 and Th2 cell differentiation |
1.85 |
3.99e-3 |
80/92 (86.96%) |
STAT1;JAG1;NFKBIA;...
|
| Hematopoietic cell lineage |
1.83 |
4.78e-3 |
90/99 (90.91%) |
CD9;IL1B;CD55;...
|
| Melanoma |
1.83 |
4.59e-3 |
68/72 (94.44%) |
CDKN1A;DDB2;BAX;...
|
| Basal cell carcinoma |
1.83 |
4.41e-3 |
41/63 (65.08%) |
CDKN1A;DDB2;BAX;...
|
| Non-small cell lung cancer |
1.81 |
6.37e-3 |
70/72 (97.22%) |
CDKN1A;DDB2;BAX;...
|
| Inflammatory bowel disease |
1.80 |
6.15e-3 |
58/65 (89.23%) |
STAT1;IL1B;MAF;...
|
| RIG-I-like receptor signaling pathway |
1.80 |
6.33e-3 |
64/70 (91.43%) |
ISG15;IRF7;NFKBIA;...
|
| Th17 cell differentiation |
1.79 |
6.12e-3 |
95/107 (88.79%) |
STAT1;IL1B;NFKBIA;...
|
| mRNA surveillance pathway |
-1.66 |
4.68e-2 |
71/98 (72.45%) |
ACIN1;PPP2R5E;PPP2R5A;...
|
| Protein processing in endoplasmic reticulum |
-1.68 |
4.49e-2 |
127/171 (74.27%) |
RPN1;MAN1A2;SEC24B;...
|
| Cysteine and methionine metabolism |
-1.68 |
4.99e-2 |
43/50 (86%) |
CTH;LDHB;BCAT1;...
|
| Ribosome biogenesis in eukaryotes |
-1.81 |
1.23e-2 |
52/108 (48.15%) |
BMS1;IMP4;GAR1;...
|
| Cell cycle |
-1.89 |
7.00e-3 |
110/124 (88.71%) |
TGFB1;CDKN2A;CREBBP;...
|
| DNA replication |
-1.94 |
5.45e-3 |
34/36 (94.44%) |
POLD1;MCM4;RNASEH2B;...
|
| Nitrogen metabolism |
-1.98 |
6.54e-3 |
16/17 (94.12%) |
CA3;CA4;CA9;...
|
| Oocyte meiosis |
-2.00 |
4.09e-3 |
90/129 (69.77%) |
ITPR2;RPS6KA6;CALML4;...
|
| Progesterone-mediated oocyte maturation |
-2.06 |
0.00e+0 |
75/100 (75%) |
MAPK14;CDC23;CCNB1;...
|
| RNA transport |
-2.12 |
0.00e+0 |
128/186 (68.82%) |
EIF2S2;EIF2S3;NUP62;...
|
| Spliceosome |
-2.64 |
0.00e+0 |
101/150 (67.33%) |
HNRNPU;SART1;HNRNPK;...
|